However, the development of a number of high affinity synthetic ligands for PPARδ has shown the receptor holds considerable promise for the treatment of T2DM, the metabolic syndrome, dyslipidemia and obesity. The gene discussed is PPARD; the disease is obesity due to melanocortin 4 receptor deficiency.